| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: ≥98%
Flucloxacillin sodium (Floxacillin, Floxapen) is a potent narrow-spectrum beta-lactam antibiotic used to treat infections caused by susceptible Gram-positive bacteria. Unlike other penicillins, flucloxacillin is beta-lactamase stable and thus has activity against beta-lactamase-producing organisms such as Staphylococcus aureus as it is. However, it is ineffective against methicillin-resistant Staphylococcus aureus (MRSA). It is very similar to dicloxacillin and they are considered to be interchangeable.
| Targets |
Cell wall synthesis
|
|
|---|---|---|
| ln Vitro |
The minimum inhibitory concentration (MIC) of flucloxacillin against Staphylococcus aureus was determined to be 0.25–2 μg/mL using the broth dilution method. When combined with amoxicillin, it exhibited significant synergistic effects against β-lactamase-producing strains, with a fractional inhibitory concentration (FIC) index ≤ 0.5, indicating additive or synergistic effects
|
|
| ln Vivo |
|
|
| Animal Protocol |
|
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
The bioavailability after oral administration is 50–70%. Metabolisms/Metabolites Metabolized in the liver. Known metabolites of flucloxacillin include 6-[[3-(2-chloro-6-fluorophenyl)-5-(hydroxymethyl)-1,2-oxazol-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. Biological Half-Life 0.75–1 hour |
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Floxacillin has not been approved for marketing in the United States by the Food and Drug Administration (FDA). It is safe for breastfeeding women and is commonly used abroad to treat mastitis in breastfeeding women. Limited information suggests that the concentration of fluoxetine in breast milk is low and is not expected to have adverse effects on breastfed infants. There have been occasional reports of penicillin-type drugs causing gastrointestinal flora imbalance in infants, leading to diarrhea or thrush, but these effects have not been fully evaluated. Fluoxetine is safe for breastfeeding women. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. |
|
| References | ||
| Additional Infomation |
Flucloxacillin is a penicillin-like compound with a side chain of 6β-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-carboxamido]. It is an antibacterial drug. It is both a penicillin-like compound and a penicillin allergen. It is the conjugate acid of flucloxacillin (1-).
An antibiotic analogue of cloxacillin. Flucloxacillin is a narrow-spectrum semi-synthetic isoxazolidinyl penicillin with antibacterial activity. Flucloxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is essential for maintaining the strength and rigidity of bacterial cell walls. This interferes with bacterial cell wall synthesis, leading to weakened bacterial cell walls and ultimately cell lysis. An antibiotic analogue of cloxacillin. Drug Indications For the treatment of bacterial infections caused by susceptible microorganisms. Mechanism of Action Flucloxacillin inhibits the third and final stage of bacterial cell wall synthesis by binding to a specific penicillin-binding protein (PBP) located within the bacterial cell wall. Cell lysis is subsequently mediated by bacterial cell wall autolysins (such as autolysins); flucloxacillin may interfere with autolysin inhibitors. |
| Molecular Formula |
C19H16CLFN3NAO5S
|
|---|---|
| Molecular Weight |
475.8512
|
| Exact Mass |
475.038
|
| Elemental Analysis |
C, 47.96; H, 3.39; Cl, 7.45; F, 3.99; N, 8.83; Na, 4.83; O, 16.81; S, 6.74
|
| CAS # |
1847-24-1
|
| Related CAS # |
Flucloxacillin;5250-39-5
|
| PubChem CID |
21319
|
| Appearance |
Solid powder
|
| Boiling Point |
677.3ºC at 760 mmHg
|
| Melting Point |
176-178ºC
|
| Flash Point |
363.4ºC
|
| Vapour Pressure |
2.86E-19mmHg at 25°C
|
| LogP |
1.681
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
758
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
ClC1=C([H])C([H])=C([H])C(=C1C1C(=C(C([H])([H])[H])ON=1)C(N([H])[C@]1([H])C(N2[C@@]([H])(C(=O)[O-])C(C([H])([H])[H])(C([H])([H])[H])S[C@@]21[H])=O)=O)F.[Na+]
|
| InChi Key |
OTEANHMVDHZOPB-SLINCCQESA-M
|
| InChi Code |
InChI=1S/C19H17ClFN3O5S.Na/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/q+1/p-1/t13-,14+,17-/m1./s1
|
| Chemical Name |
Sodium (2S-(2alpha,5alpha,6beta))-6-(((3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
|
| Synonyms |
Floxapen;Floxacillin;Flucloxacillin; Floxacillin sodium; Floxapen sodium; Sodium flucloxacillin; Monosodium flucloxacillin; Stafopen sodium salt; Staphylex Sodium salt; MFI-PC; ...; 1847-24-1; Fluorochloroxacillin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~210.15 mM )
DMSO : ≥ 100 mg/mL (~210.15 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.25 mM) Solubility in Formulation 5: 100 mg/mL (210.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1015 mL | 10.5075 mL | 21.0150 mL | |
| 5 mM | 0.4203 mL | 2.1015 mL | 4.2030 mL | |
| 10 mM | 0.2102 mL | 1.0508 mL | 2.1015 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA